Company Description
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity.
We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design.
We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease.
We initiated a Phase 2 trial of our lead drug candidate, MZE829, in November 2024.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 121 |
| CEO | Jason Coloma, Ph.D. |
Contact Details
Address: 171 Oyster Point Blvd., Suite 300 South San Francisco, CA 94080 United States | |
| Phone | (650) 850-5070 |
| Website | mazetx.com |
Stock Details
| Ticker Symbol | MAZE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001842295 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jason Coloma, Ph.D. | Chief Executive Officer and Director |
| Harold S. Bernstein, M.D., Ph.D. | President, Research and Development and Chief Medical Officer |
| Courtney Phillips | General Counsel and Corporate Secretary |
| Atul Dandekar | Chief Strategy and Business Officer |
| Charles Homcy, M.D. | Chairman of the Board, Director |
| Nancy C. Andrews, M.D., Ph.D. | Director |
| Jamie Brush, M.D. | Director |
| Alan Colowick, M.D., M.P.H. | Director |
| Sekar Kathiresan, M.D. | Director |
| Jonathan Lim, M.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 7, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 6, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Sep 13, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Aug 15, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jul 31, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 21, 2024 | DRS | [Cover] Draft Registration Statement |